The $14.75-per-share deal will add P2X3 antagonist camlipixant to GSK’s respiratory pipeline, a drug which the UK-headquartered big pharma reckons could be ready for launch in 2026, although it ...
Last year, GSK also added to its respiratory pipe with an agreement to buy Bellus Health for around $2 billion, adding a P2X3 antagonist, camlipixant, in late-stage development as a chronic cough ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GSK: Related Stocks Indices ...
We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...
The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...
GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback